Despite major achievements in the treatment ofchronic hepatitis C with the combination ofinterferons and the nucleoside analog ribavirin themajority of patients with chronic hepatitis C virus(HCV) infection cannot be treated effectively.Toimprove this response rate we used antisensetechnologies to inhibit HCV translation as possibleadditional option for experimental treatment.Antisense oligodeoxynucleotides(ODN) are short Despite major achievements in the treatment of chronic hepatitis C with the combination of interferons and the nucleoside analog ribavirin the major of patients with chronic hepatitis C virus (HCV) infection can not be served effectively.Toimprove this response rate we used antisensetechnologies to inhibit HCV translation as possibleadditional option for experimental treatment. Antisense oligodeoxynucleotides (ODN) are short